Investors Purchase Large Volume of Teladoc Health Call Options (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) was the recipient of some unusual options trading activity on Tuesday. Traders purchased 13,849 call options on the stock. This represents an increase of approximately 99% compared to the typical daily volume of 6,959 call options.

Teladoc Health Price Performance

TDOC traded up $0.07 during trading on Tuesday, reaching $6.00. 2,975,497 shares of the company’s stock were exchanged, compared to its average volume of 5,091,613. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.89. The stock has a market capitalization of $1.09 billion, a P/E ratio of -6.06 and a beta of 2.14. The company’s fifty day simple moving average is $6.30 and its 200-day simple moving average is $6.87.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. The business had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities analysts forecast that Teladoc Health will post -0.92 EPS for the current year.

Insider Activity at Teladoc Health

In related news, CEO Charles III sold 17,805 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the transaction, the chief executive officer directly owned 465,535 shares of the company’s stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its holdings in shares of Teladoc Health by 1.3% in the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock valued at $44,066,000 after buying an additional 107,400 shares during the period. Monaco Asset Management SAM purchased a new stake in shares of Teladoc Health in the second quarter worth about $26,864,000. Pale Fire Capital SE grew its holdings in Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after acquiring an additional 1,454,288 shares during the period. Quantinno Capital Management LP grew its holdings in Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after acquiring an additional 1,471,631 shares during the period. Finally, Freestone Grove Partners LP acquired a new stake in Teladoc Health during the second quarter worth about $7,338,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Canaccord Genuity Group cut their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Citigroup dropped their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Finally, Bank of America upped their target price on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.54.

Teladoc Health Company Profile

Teladoc Health, Inc (NYSE: TDOC) provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company’s offerings include Teladoc’s telehealth services, BetterHelp’s online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.